Blueprint Genetics
Uses Next Generation Sequencing (NGS) to perform diagnostics on genetic diseases.
- biotechnology
- dt and ls
- biotech and pharma
- testing
- oncology
- genetics and genomics
- dna
- neurology
- medical testing
- cardiology and cardiovascular
- genome engineering
- nordic rising star 2022
- health diagnostics
- digital pharma
- dermatology
- immune system
- ophthalmology
- gastroenterology
- hearing
- top 50 nordic rising star 2022 finland
- sequencing
- kidney
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 248 % | 27 % | 50 % | 5 % | 42 % | (1 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (37 %) | (64 %) | (26 %) | (34 %) | 15 % | (20 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (59 %) | (90 %) | (45 %) | (51 %) | 6 % | (26 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 99 % | 98 % | 130 % | 124 % | - | - | - |
Source: Company filings or news article, Dealroom estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.